Camrelizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetPD1
Clinical data
Other namesSHR-1210
ATC code
  • none
Identifiers
CAS Number
UNII

Camrelizumab (SHR-1210) (INN[1]) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.[2]

This drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019, camrelizumab is undergoing Phase II/III trials.

References

  1. ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).
  2. ^ Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. (June 2019). "Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma". Journal of Clinical Oncology. 37 (17): 1479–1489. doi:10.1200/JCO.18.02151. PMID 31039052. S2CID 141482897.
Categories